TY - JOUR
T1 - Clinical and radiological disease reactivation after cessation of long-term therapy with Natalizumab
AU - Baumgartner, Annette
AU - Stich, Oliver
AU - Rauer, Sebastian
N1 - Funding Information:
Oliver Stich, and Sebastian Rauer received consulting or lecture fees, or grant and research support from Bayer Schering, Biogen Idec, Merck Serono, Novartis, Sanofi Aventis, and Teva Pharmaceuticals. Sebastian Rauer is a founding executive board member of ravo Diagnostika GmbH, which sells medical devices for the detection of paraneoplastic autoantibodies. None of the authors has any financial or personal relationships with individuals or organizations that could inappropriately influence this submission.
PY - 2012/1
Y1 - 2012/1
N2 - Naitalizumab is a potent monoclonal antibody approved for the treatment of relapsingremitting multiple sclerosis (MS); however, little is known about the course of disease after cessation of therapy. The few existing reports describe different courses of disease after treatment discontinuation. Here we report on four MS patients who experienced clear clinical and radiological reactivation of the disease several months after cessation of therapy with natalizumab (1529 months). In all cases, there was almost no clinical or radiological disease activity during natalizumab therapy. Three patients experienced a severe clinical relapse between 3 and 9 months after therapy cessation. The fourth patient developed cerebral magnetic resonance imaging (MRI) activity showing multiple new gadolinium-enhanced lesions. Due to these observations, it is recommended to weigh up the risk of disease reactivation against the risk of progressive multifocal leukoencephalopathy.
AB - Naitalizumab is a potent monoclonal antibody approved for the treatment of relapsingremitting multiple sclerosis (MS); however, little is known about the course of disease after cessation of therapy. The few existing reports describe different courses of disease after treatment discontinuation. Here we report on four MS patients who experienced clear clinical and radiological reactivation of the disease several months after cessation of therapy with natalizumab (1529 months). In all cases, there was almost no clinical or radiological disease activity during natalizumab therapy. Three patients experienced a severe clinical relapse between 3 and 9 months after therapy cessation. The fourth patient developed cerebral magnetic resonance imaging (MRI) activity showing multiple new gadolinium-enhanced lesions. Due to these observations, it is recommended to weigh up the risk of disease reactivation against the risk of progressive multifocal leukoencephalopathy.
UR - http://www.scopus.com/inward/record.url?scp=83255176110&partnerID=8YFLogxK
U2 - 10.3109/00207454.2011.622452
DO - 10.3109/00207454.2011.622452
M3 - Journal articles
C2 - 21913869
AN - SCOPUS:83255176110
SN - 0020-7454
VL - 122
SP - 35
EP - 39
JO - International Journal of Neuroscience
JF - International Journal of Neuroscience
IS - 1
ER -
